Morphotek Secures Samples from Fox Chase to Develop Companion Tests for Oncology Drugs | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Morphotek said today that it has entered into two agreements with Fox Chase Cancer Center to acquire clinical samples that it will use to develop companion diagnostic assays for use with drugs currently under development at Morphotek.

Morphotek, a subsidiary of Eisai, said it will fund prospective and archival sample collection programs at Fox Chase to obtain samples from patients who are newly diagnosed with cancer or are being treated for a variety of tumor types.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.